Clinical trials: FL
Follicular Lymphoma
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.
- Trial name
- NCT03525665
- Testing
- Metabolic activity measured by FDG-PET
- Where
- 27 sites in Italy
- Volunteers
- 175 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Fetal Growth Restriction
Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study
One of the most challenging areas currently facing obstetricians is the detection and management of pregnancies in which the growth of the fetus is poor.
- Trial name
- IUGR (NCT01981824)
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ain Shams Maternity Hospital
Lymphoma, Follicular
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With…
- Trial name
- NCT00394836
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Follicular
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present.
- Trial name
- NCT00427856
- Testing
- Obatoclax mesylate, Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Gemin X
Follicular Lymphoma
Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma
Radiotherapy (RT) is an important option for patients with limited stage FL. The recommended approach for patients with limited stage FL by The National Comprehensive Cancer Network (NCCN) is 24Gy~30Gy consolidation RT following…
- Trial name
- NCT02449252
- Testing
- Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Wuhan University
Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world…
- Conditions
- Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
- Trial name
- ARIADNE (NCT05326308)
- Testing
- Zanubrutinib, Obinutuzumab
- Where
- 2 sites in Austria, Germany
- Volunteers
- 845 people
- Sponsor
- iOMEDICO AG
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Trial name
- UNITY-NHL (NCT02793583)
- Testing
- Ublituximab, Umbralisib, Bendamustine
- Where
- 168 sites in United States, Australia and 7 more
- Volunteers
- 710 people
- Sponsor
- TG Therapeutics, Inc.
Influenza
Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine
This is a single blind, reference drug controlled, one center viral immunogenicity and tolerability study of FluvalAB FL-K-004 Trivalent Influenza Vaccine with 6 μg HA/strain/dos antigen content to assess immunogenicity and…
- Trial name
- NCT00778297
- Testing
- Vaccination with FluvalAB FL-K-004 trivalent flu vaccine, Vaccination with FluvalAB trivalent influenza vaccine
- Where
- Hungary
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Relapsed/Refractory Follicular Lymphoma
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
This is a multicenter, single-arm, open-label, investigator-initiated, phase II clinical trial designed to evaluate the feasibility, efficacy, and safety of Mosunetuzumab in combination with Tislelizumab in patients with…
- Trial name
- NCT07031700
- Testing
- Mosunetuzumab, Tislelizumab
- Volunteers
- 22 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with…
- Conditions
- Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)
- Trial name
- NCT06980116
- Testing
- EXS73565
- Where
- 17 sites in Georgia, Greece and 5 more
- Volunteers
- 85 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Follicular Lymphoma (FL)
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.
- Trial name
- LEDA (NCT05888493)
- Testing
- Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles
- Where
- 30 sites in Australia, Austria and 9 more
- Volunteers
- 109 people
- Sponsor
- Novartis Pharmaceuticals
Follicular Lymphoma
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
This is a prospective, multiple-centers, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in high-risk treatment-naive patients with…
- Trial name
- NCT06549335
- Testing
- Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ruijin Hospital
Small Cell Lung Cancer, Uveal Melanoma
A Study of PLX2853 in Advanced Malignancies.
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
- Conditions
- Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT03297424
- Testing
- PLX2853
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Opna Bio LLC
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer
- Trial name
- NCT02440685
- Testing
- ASN002 Dose Escalation, ASN002 RD
- Where
- 14 sites in United States, Argentina
- Volunteers
- 51 people
- Sponsor
- Asana BioSciences
Health, Subjective
Florida Community-Engaged Research Alliance (FL-CEAL)
The purpose of the study is learn more about ways to help people with non-medical issues that can affect participant health. The study team will examine if Community Health Workers, members of a community who provide basic health…
- Trial name
- NCT06829485
- Testing
- Community health workers (CHW), Educational Materials
- Where
- 7 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Miami
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
This non-randomized, open label, multi-site, first-in-human, Phase 1/2 study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT05169489
- Testing
- bbT369
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Regeneron Pharmaceuticals
Relapsed/Refractory Follicular Lymphoma
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program…
- Trial name
- MosuOSSHSR (NCT07278921)
- Testing
- Mosunetuzumab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Andrés José Maria Ferreri
Caries
Effect of CPP-ACP With/Without Fl on White Spot Lesion,Salivary pH and fl Release in High Caries Risk Patients
Effect of CPP-ACP pastes with/without Fluoride on White spot lesion progression, salivary pH and fluoride release in high caries risk Patients, over 3 month period using VistaCam, Digital pH meter and Selective ion electrode.
- Trial name
- NCT03656432
- Testing
- CPP-ACP paste
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Cairo University
Follicular Lymphoma, Lymphoma
Odronextamab in Low Tumor Volume Advanced FL
The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab.
- Trial name
- NCT07128641
- Testing
- Odronextamab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Gottfried von Keudell, MD PhD
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04488354
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Calibr, a division of Scripps Research